University of North Dakota

UND Scholarly Commons
Physician Assistant Scholarly Project Papers

Department of Physician Studies

5-2019

The Impact of Medical Marijuana on the Opioid Crisis
Carl David Estep
University of North Dakota, carl.estep@und.edu

See accompanying poster for this paper at:
Follow this and additional works at: https://commons.und.edu/pas-grad-papers
Part of the Other Chemicals and Drugs Commons

Recommended Citation
Estep, Carl David, "The Impact of Medical Marijuana on the Opioid Crisis" (2019). Physician Assistant
Scholarly Project Papers. 46.
https://commons.und.edu/pas-grad-papers/46

This Scholarly Project is brought to you for free and open access by the Department of Physician Studies at UND
Scholarly Commons. It has been accepted for inclusion in Physician Assistant Scholarly Project Papers by an
authorized administrator of UND Scholarly Commons. For more information, please contact
und.commons@library.und.edu.

Running head: IMPACT OF MEDICAL MARIJUANA ON THE OPIOID CRISIS

1

The Impact of Medical Marijuana on the Opioid Crisis
by
Carl David Eastep, PA-S
Bachelor of Science, Missouri Southern State University, 2016
and
Contributing Author Daryl Sieg, PA-C

University of North Dakota in partial fulfilment of graduate studies requirements for the degree
of Master of Physician Assistant Studies
Grand Forks, North Dakota
May 2019

IMPACT OF MEDICAL MARIJUANA ON THE OPIOID CRISIS

2

Table of Contents
Acknowledgements ......................................................................................................................... 3
Abstract ........................................................................................................................................... 3
Introduction ..................................................................................................................................... 4
Statement of the Problem ................................................................................................................ 6
Research Questions ......................................................................................................................... 6
Methodology ................................................................................................................................... 7
Review of Literature ....................................................................................................................... 8
The Efficacy of Medical Marijuana for Acute Pain. ................................................................................ 8
The Efficacy of Medical Marijuana and Cannabinoids for Chronic Pain .............................................. 11
Addiction Profile of Medical Marijuana and Prescription Opiates. ....................................................... 16
Adverse Effects of Medical Marijuana and Prescription Opiates........................................................... 19
Quality of Life When Using Medical Marijuana and Prescription Opiates............................................ 24

Discussion ..................................................................................................................................... 30
Application to Clinical Practice .................................................................................................... 33
References ..................................................................................................................................... 34

IMPACT OF MEDICAL MARIJUANA ON THE OPIOID CRISIS

3

Acknowledgements
I would first of all like to thank my family in supporting my decision to return to school
and become a Physician Assistant. This is especially true for my wife, Gwen. When I started off
on this journey, I quickly developed a sensation of overall suffering due to the thousands of
hours spent studying, completing clinical requirements, and the perceived loss of my freedom.
In retrospect, it was my family that suffered most. I missed countless hours of family time and
activities over the past two years, and they deserve the recognition for my accomplishment more
than I do. I would like to thank my advisor, Daryl Sieg, PA-C for his input on this project as
well. When I needed direction for this assignment, he was always available to provide direction
on a moment’s notice. I would also like to thank the remaining Physician Assistant program
instructors and staff for their instruction and guidance over the past two years. Due to their
dedication of the instructors, I always felt like more like I was being mentored or groomed for
my future role as a Physician Assistant rather than a mere student that was just passing through.
I would like to identify specific instances regarding their professionalism, but this would require
a completely new topic for this project. Thank you, Kara Hendrickson, Angie Belbas, and
Rhonda McDaniel, for being there to guide me through the clerical and testing issues that I
encountered. I would also like to thank Dr. Corey Jackson for his guidance in selecting a topic
for this project, and for his guidance during my primary care clinical rotation. Finally, I would
like to thank Trish White from the math department at Ozark Technical College, Jill
Ehrmantrant, DPT, and Catherine Corey for their valuable input on this project.
Abstract

IMPACT OF MEDICAL MARIJUANA ON THE OPIOID CRISIS

4

In light of the current opioid crisis, research is needed to identify alternative treatments for acute
and chronic pain. With medical marijuana being made available by rapidly changing state laws,
it is prudent to identify what role it may play in pain control. This comprehensive literature
review was conducted to determine what is known as to the effectiveness of medical marijuana,
cannabis, or cannabinoids for treating acute and chronic pain as compared to prescription
opiates. An additional comparison was also made between the addictive properties and adverse
effects of medical marijuana and prescription opiates. The final parameter evaluated was the
effects of these substances on the individual’s quality of life. This comprehensive literature
review revealed there is no use for medical marijuana in an acute pain setting, and in fact it may
actually cause harm by making acute pain harder to control. In contrast, according to the current
literature, medical marijuana has the potential to play a positive role in the treatment of chronic
pain. This review highlights the potential for both substances to have addiction issues to varying
degrees, but prescription opiates had a higher incidence of overdose-related deaths than did
medical marijuana. When the adverse effects between the substances were compared, memory
problems were associated with medical marijuana, especially if use was started in the teenage
years, while respiratory depression is closely associated with prescription opiates and could
result in death.
Introduction
Now, more than ever, the debate rages about the manner in which prescription opiates
should be used for pain control. The discussion revolves around the marked increase in
overdose-related deaths due to opiates. According to the 2017 National Drug Threat Assessment
published by the U.S. Drug Enforcement Agency (DEA), the yearly overdose-related deaths
have surpassed the combined deaths related to firearms, motor vehicle crashes, suicide, and
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homicide (2017). While this data represents overdose-related deaths caused by all prescription,
diverted, and illicit drugs, the DEA data indicates that controlled prescription drugs have
“outpaced those for cocaine and heroin” (2017). Another trend noted by the DEA was that
controlled prescription drug users have transitioned to heroine because it has similar effects to
prescription opiates, and it can be obtained for less money than controlled prescription drugs.
Since the introduction of pain as the fifth vital sign, pain control has been used as a tool to
measure patient satisfaction with their healthcare provider. An article published in the American
Journal of Public Health notes that healthcare providers experience decreases in compensation
and promotion due to the Hospital Consumer Assessment of Healthcare Providers and Systems
(HCAHPS) questionnaire, which asks patients “How often did the hospital or provider do
everything in their power to control your pain?”. This article further notes that:
The link between patient satisfaction scores and pain management plays out daily in
physician offices and emergency departments as physicians who recommend physical
therapy and nonopioid pain management encounter resistance from patients who simply
want a quicker “solution” with pain pills. This leaves well-meaning professionals with
the unsavory choice of prescribing opioids or facing dissatisfaction from disappointed
patients on patient surveys (Adams, Bledsoe, & Armstrong, 2016, p. 985-6).
Likewise, Makary, Overton, & Wang published an editorial in the British Medical Journal
discussing the fallacy of considering pain as the fifth vital sign and how this has contributed to
the opioid crisis (2017). Regardless of the causative factor, prescription opiates have now come
under the scrutiny of federal regulatory organizations due to the increased abuse and mortality.
According to the National Institute on Drug Abuse (2018), 19,354 people died due to
prescription opioid analgesic overdoses in 2017 alone; a number that has more than doubled
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since 2002. These circumstances have increased the need for healthcare providers to make
alternative therapies available. One such therapy with increasing acceptance in the public and
medical community is medical marijuana. As of 2018, 33 states have adopted the use of
marijuana for medical purposes, and 11 states and the District of Columbia have passed laws that
make recreational marijuana possession and use legal (National Conference of State Legislatures,
2018). Despite the federal laws that prevent the possession and use of marijuana, voters at state
levels have chosen to accept the idea that marijuana has potential for medical purposes. This
push by the voting population ensures that healthcare providers will encounter patients who are
using marijuana the medical community know as much information as possible as to the effects
of these drug on their patient’s health.
The purpose of this study is to determine if medical marijuana is a safer alternative than
prescription opiates for the control of acute and chronic pain.
Statement of the Problem
Despite the current opioid crisis in America, healthcare providers are left with few other
options for treatment of severe acute pain and control of chronic pain. While there are a few
procedures that exist to alleviate some acute pain and chronic pain processes, opiates continue to
be the mainstay treatment for syndromes where a pain alleviating procedure has yet to be
discovered. Unfortunately, the risks in using opiates for pain control may outweigh the benefits.
Accidental opiate overdoses are increasing steadily, and opiate addiction rates are at an all-time
high (National Institute on Drug Abuse, 2018). Medical marijuana may be able to play a role in
the treatment of acute pain and control of chronic pain, but more studies are needed to determine
its efficacy, and more importantly, if it is a safer alternative that prescription opiates.
Research Questions
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Is the efficacy of medical marijuana greater than prescription opiates for treating patients
with acute pain?
Is the efficacy of medical marijuana greater than prescription opiates for treating patients
with chronic pain?
Does medical marijuana have a safer addiction profile than prescription opiates?
How do the adverse effects of medical marijuana compare to the adverse effects of
prescription opiates?
How does medical marijuana affect the quality of life when compared to prescription
opiates?
Methodology
This comprehensive literature review was conducted by searching PubMed, CINAHL,
PsychInfo, and the Cochrane Database. The searches were filtered so that only peer-reviewed
articles from randomized controlled trials, meta-analyses, and systematic reviews were retrieved.
All were required to have been peer reviewed. A total of 10,274 articles were identified. This
review includes articles published between 2008 and 2018 with one exception, a randomized,
double-blind, placebo-controlled trial that was published in 2007. The exception was made due
to the quality of the study. Key words used to conduct the search were: marijuana, medical
marijuana, cannabis, cannabinoid, acute pain, chronic pain, opiates, opioids, addiction, addiction
profile, mortality, opioid deaths, marijuana deaths, quality of life, dronabinol, Sativex, nabilone,
dependence, and withdrawal. The databases were searched using an advanced search builder
using AND or OR for each research question that was proposed. Two additional publications
were included in this review after being discovered in the references of other included articles.
The available literature was narrowed further after a review of the abstracts to determine if the
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studies were human studies that were related specifically to the five proposed research questions.
At the end of the search process, the available qualifying data was limited, which is likely due to
marijuana’s current legal classification preventing larger, high quality studies.
Review of Literature
The Efficacy of Medical Marijuana for Acute Pain.
Stevens and Higgins (2017) conducted a systematic review of the literature to evaluate
published data concerning the use of cannabinoids for the control of acute pain. They initially
identified 310 articles, but only seven met the inclusion criteria, which consisted of being a
human randomized controlled clinical trial including an evaluation of a cannabinoid medication
in the setting of acute pain when compared against placebo or another comparator. The final
data used by the authors for their systematic review was published between 1981 and 2013 and
included a total study population of 611 patients. Five of the randomized controlled trials
demonstrated that the use of cannabinoids for acute pain was equivalent to placebo. Of the
remaining two randomized controlled trials, one concluded that placebo was more effective than
cannabinoids (p<0.05), and the final study concluded that cannabinoids were more effective than
placebo. However, the final study was noted to have a poorly explained methodology, which
made the conclusion suspect. The data analyzed multiple doses on the cannabinoid over
different time intervals with all of the p-values less-than 0.05. In addition, the authors note that
the data used for their systematic review failed to demonstrate any synergistic analgesic benefits
provided by cannabinoids when used in conjunction with opiate, though the p-values studies are
all greater than 0.5.
The authors conducted a thorough evaluation of available data to include as much
information as possible. In addition, they attempted to avoid as much bias as possible, and they
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went to great lengths to indicate where and how some bias might have been introduced. The
design also allowed the evidence to be used across a broad range of clinical situations because it
evaluated several different types of pain and was not limited to specific age group. However,
there were several limitations of the study including limited sample sizes, the small number of
studies included in the analysis, and the age of some of the studies included. Finally, the
reporting of the data indicates that no synergistic affects are achieved when marijuana is used in
conjunction with oral analgesics, but the p-values listed in the tables do not support this
conclusion.
Unlike the systematic review of past literature as above, Solattolo et al. (2018) conducted
a retrospective study with the purpose of determining if pre-injury marijuana use was associated
with an abnormal pain response following traumatic injury. The population targeted for the study
consisted of patients who were involved in motor vehicle crashes (MVC). The data for the study
was obtained by trauma registry services at four trauma centers; three hospitals were located in
Colorado and one was located in Texas. A total of 261 patients were enrolled in the study over a
four-month period. The study was designed to categorize the population into three separate
categories: no marijuana or drug use, medical or recreational marijuana use but no drug use, and
drug use but no medical or recreational marijuana use. For clarification the authors defined
drugs as amphetamines, barbiturates, benzodiazepines, cocaine, methamphetamine, and opiates.
This distinction allowed the independent evaluation of marijuana-use only as well as marijuana
use combined with other elicit substances. After identifying the study population and obtaining
the data, the authors then compared daily Pain Scores and opiate consumption throughout the
hospital stay. With regard to pain scores, the study showed that individuals identified as nonmarijuana and non-drug users had significantly lower pain scores than individuals who were

IMPACT OF MEDICAL MARIJUANA ON THE OPIOID CRISIS

10

identified as episodic or chronic marijuana users. Additionally, episodic users had higher pain
scores than chronic users (p < 0.001) and non-users (p < 0.001). Pain scores between marijuana
users who were not drug users and marijuana users who were drug users were not significantly
different. The authors also noticed that drug users who did not use marijuana reported higher
pain scores than drug users who reported episodic or chronic marijuana use. Upon evaluating the
data concerning opiate consumption, the study indicates that those participants who were
identified as non-marijuana and non-drug users consumed significantly lower amounts of opiates
than participants who were identified as marijuana users but not drug users (p < 0.049). Chronic
and episodic users of marijuana had similar opiate consumption patterns (p = 0.41). When
participants who used marijuana and drugs were compared against participants who used
marijuana but not drugs, there were no significant differences noted in opiate consumption.
Finally, the study found that chronic marijuana users who also use drugs consumed significantly
more opiates than drug users who episodically use marijuana (p = 0.01) and drug users who did
not use marijuana (p = 0.05).
While this study does not specifically evaluate the use of marijuana in patients with acute
pain, it does provide insight into some potential negative effects that marijuana could have on
patients when attempting to treat acute pain, at least in patients with traumatic injuries. The data
obtained during the study indicates that marijuana use could increase the amount of opiates
required to control acute traumatic. There are some limitations to how the information from the
study might represent the actual population. For instance, the study was conducted using 4
hospitals, three of which were in Colorado and one in Texas. Colorado has laws that permit
medical and recreational marijuana use, but Texas does not permit either medical or recreational
use. There is no information regarding how many study participants were enrolled at each
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facility, but the ease of obtaining marijuana is known to affect the rate of its use. In addition,
marijuana use was noted to be greater in Colorado than in Texas. An additional study comparing
states with similar marijuana use laws would increase the validity. Another factor limiting the
use of the study data is the fact that the study population size was small, which the authors
acknowledged. They also noted that this was just a pilot study designed to guide future research.
Additional limiting factors of the study include relying on patients with negative drug screen to
report whether they used marijuana episodically and classifying patients with an altered mental
status and negative drug screen as non-users, both of which the authors pointed out. Finally, the
conclusions found in the study cannot be generalized to all patients because it only evaluated
patients involved in motor vehicle crashes, which confounds the data due to varying traumatic
injuries. Regardless of the limitations, the data did indicate that marijuana use may complicate
attempts to control acute pain, which warrants further investigation.
The data in the literature regarding the use of marijuana and other cannabinoids to control
acute pain is limited, especially data from current, high quality, randomized controlled trials. No
evidence was discovered during this literature review that suggests that marijuana or other
cannabinoids have a role in the management of acute pain. In fact, there is cursory evidence that
suggests that marijuana and other cannabinoids negatively impact the management of acute pain
after traumatic injuries.
The Efficacy of Medical Marijuana and Cannabinoids for Chronic Pain.
While the evidence discovered during this review did not support the use of marijuana or
cannabinoids for the treatment of acute pain, there is likely a role it can play in the treatment of
chronic pain. Wilsey et al. (2008) recruited 44 patients, 23 men and 21 women, to participated in
a double-blind, placebo-controlled, crossover study to evaluate the analgesic efficacy of smoked
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marijuana in the treatment of neuropathic pain. Of these 44 initial patients, 32 completed all
three of the study sessions, which consisted of three, six-hour experiment sessions where
standardized doses of smoked marijuana, either 3.5% THC content or 7% THC content, or
placebo were administered. The main question the authors wanted to answer was whether
smoked marijuana had any analgesic effects on neuropathic pain or evoked pain. The research
showed that smoked marijuana showed a statistically significantly (p = 0.016) analgesic effect
when compared to placebo for neuropathic pain. In fact, the study found that the 3.5% dose and
the 7% dose of THC had equal analgesic cumulative effects on pain (p <0.01) indicating a
threshold, which the authors indicate may allow analgesia at a lower dose and thereby decrease
psychoactive side effects. However, they also noted that the analgesic benefits began to diminish
within one to two hours after the last dose. Though smoking marijuana was shown to have an
analgesic effect on pain that was already present, it did not show that it diminished evoked pain.
An additional finding in the study was that marijuana caused a decline in cognitive performance,
which prompted the authors to include a warning about its use in patients when learning and
memory are vital to work and lifestyle.
This was a well-designed, tightly regulated study that made every attempt to reduce bias.
Even the delivery methods used to ensure that every patient received as close to the exact same
dose as possible was well planned. The study population was diverse, and the neuropathic pain
that was evaluated in the study was well represented. The major limiting factors to the study was
its size, and the short duration over which it was conducted. In addition, the authors failed to
disclose any shortcomings of the study, which may indicate that some bias did exist.
Unlike the above research, the following study takes a more uncontrolled approach at
trying to determine where marijuana lies in the spectrum of chronic pain management. The
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study was a result of cooperation between the Australian Government and the National Health
and Medical Research Council of Australia. Campbell et al. (2018) designed the study in order
to investigate marijuana use in patients who had chronic noncancer pain and were taking opiates
for pain management. They examined why marijuana was used, its perceived effectiveness, and
the associations between the amount of marijuana used and pain, mental health, opioid use, the
effects of marijuana use on pain severity and interference over time, and the potential opioidsparing effects of marijuana. In contrast to most other studies, patients with complex physical
problems, substance use, and mental health issues were not excluded because they represent a
significant proportion of the population living with chronic non-cancer pain. People who were
prescribed opioids as a replacement for heroin dependence, and those with cancer were excluded
from the study. The study enrolled 1,514 patients and followed them over a four-year period. At
the end of the four-year timeframe, 1,217 patients remained in the study. Of those participants
initially enrolled in the study, the median amount of time that they had experienced chronic pain
was 10 years. Back or neck complaints were the most common cause of chronic pain followed
closely by arthritis, which consisted of 1,159 and 933 participants respectively. At the
conclusion of the study, no relationship was found between the consumption of marijuana and a
decrease in pain with a mean effectiveness of seven on a scale of 1 - 10. Also of note was that
the use of marijuana in the cohort increased from 24% at initiation of the study to 60% at the
study’s end. In addition, it was reported that participants claimed that marijuana reduce their
pain. However, during the statistical analysis of pain scores, no association was found between
marijuana use and the reduction of pain, though no p-value or confidence interval was reported.
Greater pain severity scores were noticed in users who reported less frequent marijuana use, and
users who reported daily or near-daily marijuana use (95% CI [1.01, 1.29]) than did non-users.
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Finally, greater pain interference scores, lower pain self-efficacy, and higher levels of anxiety in
patients who used marijuana than in participants who did not use marijuana, which is consistent
with other studies evaluated here.
Compared to other studies evaluated in this project, this study was notably longer and
enrolled a higher number of participants, and the results of the study were very different than the
results of the smaller studies. These differences are possibly related to the enrollment of
participants who were selected simply because they had chronic pain. Many of the other studies
selected participants based on the type of pain experienced. The different results could also be
related to the increased size of the cohort. This study relied upon the individual participants to
report how often they used marijuana and rate their pain on a scale of 0 to 10, which could also
explain why the statistics do not agree with the reports of decreased pain. Another problem with
this particular study was the lack of control over how marijuana was obtained and used. At the
time the study was conducted, marijuana possession and its use were illegal in Australia. As a
result, the participants obtained their own illegal marijuana from individual sources, which
leaves the study open to some scrutiny regarding comparison to recreational marijuana and
cannabinoids and smoked marijuana with a known Tetrahydrocannabinol (THC) and
Cannabidiol (CBD) content.
This study by Nurmikko et al. (2007) was well controlled and executed in comparison to
the study by Campbell et al. (2018). This was a five-week study designed to evaluate the effect
of oral-mucosal Sativex on pain and allodynia. The cause of the neuropathic pain varied from
post-traumatic injuries, post-infection, vascular, and idiopathic causes. The study was a
randomized, double-blind, placebo-controlled, parallel design trial that enrolled 125 participants.
When the study began, 63 of the participants were randomly assigned to the Sativex group and
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62 were assigned to the placebo group. The participants were allowed to remain on their current
daily pain medication regimen throughout the study, and the participants were allowed to selftitrate their daily mucosal sprays of Sativex to find the optimal dose to treat their pain. They
were also required to record their daily pain scores, adverse events, and number of sprays used.
At the end of the trial, 50 participants remained in the Sativex group and 55 remained in the
placebo group. The majority of the participants in the Sativex group, a total of 11 patients,
withdrew from the study due to adverse effects, and those who withdrew from the placebo group,
a total of five patients, did so because of lack of effect. At the conclusion of the study, the data
compiled lead the authors to report a decrease in pain (p = 0.004) that became evident during the
second week when self-titration began. Specifically, they reported that 26% of patients in the
Sativex group had a 30% reduction in pain scores (p = 0.007), and 20% of participants in this
group had a 50% reduction in pain scores. Furthermore, they reported that dynamic allodynia
had a mean reduction of 20% (p = 0.042) in the Sativex group compared to 5% in the placebo
group. At the end of the five-week trial, participants were offered a chance to be involved in an
extended portion of the study, and 89 of the participants accepted the offer. Of those who agreed
to coninte in the extended study, 56 (63%) withdrew before it ended, and 18 (50%) of them cited
adverse effects as the reason. The authors subsequently concluded that, while medical
cannabinoids may reduce chronic, peripheral, neuropathic pain, it only did so as an addition to
existing medications, which consisted mainly of prescription opiates.
The fact that this study was a randomized, double-blind, placebo-controlled experiment
makes it less likely to include bias by those involved and it increases the significance of the
results. However, the small study size and short duration of the study cannot be disregarded.
The authors did extend the study duration, but this extended participation was plagued with

IMPACT OF MEDICAL MARIJUANA ON THE OPIOID CRISIS

16

adverse effects, and the study population was even smaller than the original five-week study.
Regardless, current literature suggests that medical marijuana, and Sativex specifically, could
potentially play a role in the management of chronic neuropathic pain, but, when compared with
results of other trials, it is still unclear whether medical cannabis, and Sativex specifically, can
reduce pain alone or whether it is best used along with other oral analgesics.
Addiction Profile of Medical Marijuana and Prescription Opiates.
While there was little information discovered regarding the addictive nature of marijuana
or cannabinoids, there is information available that indicates that dependence and tolerance can
occur with long-term use. According to the National Institute on Drug Abuse, the use of
marijuana can result in the development of marijuana use disorder. Marijuana use disorder
consists of withdrawal symptoms, which include disruption of sleep, irritable mood, marijuana
craving, decreased appetite, and restlessness (2018). Many of these symptoms are also
associated with the use of prescription opiates. The National Institute of Drug Abuse also lists
long-term memory problems with repeated, heavy use of marijuana, especially during youth,
cough and bronchitis, and risk of schizophrenia in genetically susceptible individuals (2017).
These latter side effects are not shared with prescription opiates.
Literature might be sparse regarding the addiction profile of marijuana and cannabinoids,
but there is ample documentation of detrimental side effects and unintended consequences of
prescription opiates. In 2015 Vowles et al. published their results of a systematic review in the
journal Pain. The review was conducted in order to determine rates of problematic opioid use as
reported in the current literature. The classification of problematic opioid use was limited to
three categories. The first category, misuse, was defined as opioid use contrary to prescribed or
directed patterns, regardless of whether harm or adverse effects were present or not. The second
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category, abuse, was defined as intentional use of opiates for non-medical purposes. The third
category, addiction, was defined as a pattern of continued use despite suffering harm or knowing
that harm could occur. The authors identified 38 studies for the systematic review that met the
inclusion criteria. Of the 38 studies identified, 76% of them provided data regarding misuse and
32% provided data regarding addiction. Only one study was identified that could provide data
on opioid abuse. After statistical analysis of the data, the authors reported that the rate of opioid
misuse on average was 1 of 4-5 people (21.7% – 29.3%), and addiction occurred in 1 of 10-11
people (7.8%-11.7%). The authors did not report the rate of opioid abuse that was contained in
the single study, but they were able to report two key conclusions at the end of this systematic
review. The first conclusion was that opioid misuse and opioid addiction each consist of distinct
patterns of problematic opioid use when interpreted using the set definitions provided. The
second conclusion was that opioid misuse was more common than opioid addiction.
The obvious problem with this systematic review is the small number of studies included.
Only one study was identified that evaluated the abuse category defined by the authors, which
led them to omit this data from the results. There was also a huge variation between the study
types and designs, as pointed out by the authors, which led to large ranges of raw data when
applied to rates of opioid addiction and opioid misuse. For instance, the raw data indicated that
0.08% to 81% of individuals misused opiates. These large ranges led the authors to separate the
studies into high-quality and low-quality categories and further statistical analysis had to be used.
The authors also indicated that the broad range of data examined during the study “will likely
continue to cloud our ability to make precise estimates.” (Vowels et al., 2015).
As mentioned previously, one of the main reasons that legislators wish to curtail the use
of prescription opiates is the rapidly increasing number of opioid related deaths. This is also one
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of the reasons that medical marijuana and cannabinoids should be researched. In 2017,
Livingston, Barnett, Delcher, & Wagoner conducted research to determine if the legalization of
recreational marijuana in Colorado influenced the rate of opiate related deaths. To do so, they
evaluated deaths that occurred in Colorado between 2000 and 2015, which went three years
beyond the initial legalization or recreational marijuana in 2012. They compared the data
obtained in Colorado against Nevada, which only allows the sale of medical marijuana. They
also compared the data against Utah where marijuana possession and use in any capacity is still
illegal under state law. While compiling the data, the authors noticed an increased rate of visits
to the emergency department for cannabis-related emergencies by both adults and children.
However, the data also indicated a statistically significant decrease in opiate related deaths in
Colorado (CI 95% [-1.34, -0.03]). Specifically, the statistical data indicated opiate related deaths
in Colorado decreased by 6.5% in the two years after recreational marijuana was legalized.
The data obtained by Livingston et al. (2017) was the result of a long-term and inclusive
research design. They evaluated data over a 15-year time span, which would likely be a true
representation of data prior to legalization of recreational marijuana. However, the evaluation of
two years of data after the legalization of recreational marijuana provides only a short sample in
time. The results of these two years may be somewhat less reliable. That is to say that it would
be somewhat naïve to base long term decisions off of the post-legalization results, which the
authors indicated in their publication. However, the use of two other states, Nevada and Utah, as
control groups serves to further increase the validity of the data. The authors also noted that the
confounder of changing policies during the interrupted time-series design of their study could
possibly affect the outcome of the data. In this particular instance, Colorado changed the
requirements of their prescription drug monitoring program, which the authors noted can also
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cause a decrease in opiate related deaths. The authors made every attempt to offset this change
with statistical controls. Overall the data obtained, and the subsequent interpretation are reliable.
However, additional studies are needed so that long-term decisions can be based on more solid
reserch.
Adverse Effects of Medical Marijuana and Prescription Opiates.
In order to avoid the same pitfalls that came to light after the decision was made to
routinely treat pain with prescription opiates, it is imperative that healthcare providers know
about any potential adverse effects that are associated with long-term use of marijuana. The
negative impact associated with prescription opiate use has been well documented, but there is
still a need to weigh the side effects of long-term marijuana and cannabinoid use against
prescription opiates. Gruber et al. (2016) conducted a three-month, longitudinal study in effort
to determine if medical marijuana use impacted the executive function of patients who use it.
The authors enrolled 24 participants at the beginning of the study with the intention of
reassessment of executive function at three, six, and twelve months. Participants were between
32 and 74 years of age. Inclusion criteria required the participants to be either marijuana naïve
or to not have used marijuana in the past 10 years. Neurocognitive assessments were completed
on all participants prior to initiation of treatment. Participants also underwent neuroimaging with
magnetic resonance imaging (MRI) prior to beginning the study. The participants were then
evaluated monthly by telephone to obtain information regarding the type, oils, tinctures, edibles,
or vaped, and the frequency, magnitude, and strain of marijuana used. At three months, the
participants were evaluated at a check-in visit and repeated all of the neurocognitive assessments.
The published results consisted of the data obtained during first three-month check-in visit. The
preliminary data indicated that the participants completed the skills evaluated in the
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neurocognitive assessment faster during the second visit that they had before treatment with
medical marijuana began. The participants also reported lower levels of depression and lower
levels of sleep disturbances. In addition, a better quality of life was reported because the
participants were able to participate more in things they liked doing. The number of opiates used
before treatment reportedly decreased from a mean of 5.95 doses per week before starting the
study to 2.27 doses per week at the three-month check-in. A decrease in the number of
antidepressants, mood stabilizers, and benzodiazepines was also noted. It was speculated that
these improvements were seen because of a decrease in interference from the chronic conditions
afflicting the participant, but this line of thinking is a longshot at best. In contrast to most other
published studies that document cognitive deficits occurring in patients who use marijuana, the
data obtained in this study indicated an improvement in cognitive function. However, Gruber et
al. noted that the majority of the studies that were evaluated in this review evaluated cognitive
function as a secondary measure (2016). In contrast, this study was designed to measure
executive function primarily. Regardless, the small sample size and short duration limit its
reliability, which the authors acknowledge. The study was intended to be carried out over a oneyear time frame, and it is unknown why the authors chose to publish the data and conclusions
obtained from the first three-month visit. The authors also chose to allow the participants to
obtain medical marijuana on their own during the study instead of supplying the medical
marijuana with a known THC and CBD concentration, and this detail further detracts from the
study’s validity. Another confounding factor was that the participants were completing the same
neurocognitive assessment tests at each three-month check-in, and this brings into question about
the improved cognitive test results being a product of a decrease in chronic symptoms or from
familiarity with the testing process. Furthermore, the reporting of the initial data instead of the
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data obtained at the end of the entire study makes the results less reliable in regard to long-term
viability of medical marijuana use. Additionally, a control group would have increased the
overall reliability of the data obtained initially and at the conclusion of the study. When
considering this study as a whole, little confidence is instilled concerning the validity of the
results.
Volkow, Baler, Compton, & Weiss (2014) conducted a review of the current science
concerning the effects of marijuana use. The review and subsequent publication in The New
England Journal of Medicine exposed several adverse effects that are possibly caused by
marijuana. The first adverse effect broached is the problem with addiction, and the authors
indicated that 9% of those who experiment with marijuana became addicted, and this number
increases to about 16% if the experimentation started as a teenager. Among teenagers who
smoke marijuana daily, 25% - 50% will become addicted. The second adverse effect cited
concerns memory. The authors reported that short-term use will impair short-term memory
function and cause problems such as difficulty learning, impaired motor coordination, and
altered judgement It can also cause paranoia and psychosis in high-doses. Long-term or heavy
use was reportedly associated with addiction, alterations in brain development, poor educational
outcomes, cognitive impairment, diminished life satisfaction and achievement, chronic
bronchitis, and increased risk of chronic psychosis disorders such as schizophrenia, especially
with a genetic predisposition. It was also associated with an increased risk of anxiety and
depression. Most of the memory related problems were the result of marijuana use during
adolescents, which caused impaired neural connections.
This review provides a good summarization of the available current science at the time it
was written. At least it summarizes what could be considered common knowledge inside the
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medical community, but it is hard to determine how the authors discovered the “science” used
for the data in the article because no methodology was discussed in the publication. The authors
did include a comprehensive list of the limitations of the evidence, which included the inability
to establish an unquestionable relationship between marijuana use and specific pathologies due
to confounding factors, for example, causing lung cancer. They also pointed out the need for
further research based on their discoveries, such as achieving a better understanding on how
marijuana affects memory and age-related cognitive decline. Also, of note is that many of the
findings of this review are in-line with more current data released by the National Institute on
Drug Abuse.
Leonard Paulozzi conducted this review of available literature “from the first published
reports through 2011 …” (2012) in order to provide an epidemiological perspective of
prescription drug overdoses. He organized his review into host, agent, and environment
classifications. Paulozzi noted that the first report of an increase in drug poisoning mortality
was issued in 1998 by the National Center for Health Statistics, which stated that drug poisoning
mortality had increased 25% between 1985 and 1995. The 1998 report indicated that the
increase in mortality was a result of opiates but distinguishing between prescription opiates and
heroine was not possible due to documentation issues. However, in 1999 all deaths were coded
differently, which provided a distinction between legal and illicit drugs. After 1999, the drug
poisoning rates steadily increased and in 2008 the yearly deaths surpassed motor vehicle deaths.
According to Paulozzi’s research, the increase in drug poisonings has been driven by prescription
drugs, and prescription opiates specifically. While evaluating “host” factors, Paulozzi
discovered that men were more likely to die from a drug overdose than women. In contrast,
more women than men are prescribed potential drugs of abuse. Overdose rates were the highest
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between the ages of 45-54 for both suicides by overdose and unintentional overdose. He also
noted that those who overdose on prescription drugs generally had a greater number of medical
conditions. Paulozzi’s “agent” category evaluated many different types of prescription
medications including opioid analgesics. Paulozzi’s review revealed that oxycodone,
methadone, and hydrocodone were the most common opiates associated with overdose deaths
and emergency department visits, which he noted are obtained by prescription and other nonmedical sources. Among the users who obtained opiates through nonmedical sources, most
reported obtaining them for free from a friend or relative. In addition, most of the friends or
relatives got them from a doctor. Of those patients who died of prescription overdoses, more
than half obtained the drugs without prescription. The “environmental” factors reported by
Paulozzi indicate that most opioid deaths occured at home.
This review did a good job of illustrating the destructive nature of opioids. It provides
even further insight into how race, socioeconomic status, and urban living versus rural living
determined risk for prescription related deaths. However, it did not provide the methodology
used to discover the information used in the review. Paulozzi willingly acknowledged the
limitations of his data, most of which seemed beyond his control. For example, the stigma
regarding illicit drugs and abuse of prescription drugs likely prevented some reporting of events.
The information obtained during the review six years ago is in-line with what is currently
unfolding today.
The available literature makes it clear that there are adverse effects associated with both
prescription opiates and marijuana. One big difference between the two substances is that no
mention of death by overdose of medical marijuana or cannabinoids was located in the literature.
The same cannot be said about prescription opiates. In contrast, the potential death from using
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prescription opiates is a well-known fact and this is the driving force behind solving the current
opioid crisis. This literature review did not look at other factors that caused death while using
marijuana or synthetic cannabinoids, deaths related to driving while under the influence of
marijuana or other cannabinoids.
Quality of Life When Using Medical Marijuana and Prescription Opiates.
Quality of life is another measurement evaluated when treating pain.one measurement,
and this is especially important when treating chronic pain.
In order to examine long-term effects of medicinal marijuana for pain and functional
outcomes, specifically in patients with treatment-resistant chronic pain, Haroutounian et al.
(2016) conducted a prospective, open-label study that started with 206 enrolled participants and
ended with 176 participants. At the beginning of the study, participants were allotted a monthly
dose of marijuana products in either smoked marijuana, edibles, or in an olive oil extract. The
THC concentrations of the monthly allotment were variable between the means of ingestion.
The administration of the marijuana was self-titrated starting at one puff of smoked marijuana or
one drop of the oil per day and increased to a maximum frequency of three times per day until
pain relief was obtained or intolerable side effects occurred. The marijuana could be titrated to a
higher dose during subsequent months if pain relief was not achieved and no side effects
occurred. The marijuana treatment was added to existing pain treatment, and patients were asked
to decrease the use of other analgesics if possible. The primary outcome that the authors hoped
to achieve was a decrease in pain. The secondary outcome was that an increase in quality of life
would be achieved along with a reduction in prescription opiate use. At the end of the study
period, pain scores decreased from 83.3 (95% CI [79.2 – 87.5]) at baseline to 75.0 (95% CI [70.8
– 79.2]) on the S-TOPS scale. Further analysis revealed that pain system scores decreased in
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65.9% of the participants from baseline, while 8% reported no change from baseline and 26.1%
reported that their pain increased (Haroutounian et al. 2017). The secondary outcomes of the
study were promising as well. At the beginning of the study, 73 of the participants enrolled in
the study were on opiates for their chronic pain. Of those 32 participants were able to
discontinue their opiate medications at follow-up, which was a 44% reduction from baseline (P <
0.001). In addition, some participants were taking opiates and tramadol to control their pain, and
at the end of the study, no participants were taking both tramadol and opiate medications.
Finally, multiple measures of quality of life were assessed at baseline and at the end of the study.
The results showed that family-social disability, role-emotional disability, satisfaction with
outcomes, and pain interference were all improved during the course of the study (p < 0.001).
While the range of pain diagnoses was fairly broad, the exclusion criteria limited the
enrollment of many of the subgroups of people who report chronic pain most frequently. For
example, people were excluded if they had a previous history of drug abuse or psychiatric
problems. In addition, no control group was used in the study, which makes the results less
reliable and this was pointed out by the author. Another problem with the study was the lack of
control over the concentration of THC and CBD. The authors report a variability in THC
concentration between 6% and 14% in the smoked marijuana, and the THC concentration of the
edible formulations varied from 11% to 19% (Haroutounian et al. 2017). The study length gave
some validity and insight to potential long-term benefits, but the number of participants was still
lower than ideal. Overall, the study indicates that, while cannabis may very well increase the
quality of life measures in people with chronic pain, more long-term, randomized controlled
trials are needed.
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This systematic review and meta-analysis, conducted by Goldenberg, Reid, IsHak, &
Danovich (2017), was an attempt to understand the relationship between marijuana,
cannabinoids, and health related quality of life (HRQoL). In order to be included in the
systematic review, articles had to be in English and be peer reviewed, had to focus on marijuana
or cannabinoids, and had to measure HRQoL and report an outcome related to overall HRQoL or
domains-specific to HRQoL. A total of 20 studies met the inclusion criteria, but nine of the
studies failed to report measure of variability so their data was excluded. Within the articles, the
authors identified seven different categories of disease, pain, multiple sclerosis (MS),
amyotrophic lateral sclerosis (ALS) and traumatic brain injury (TBI), cancer-related anorexiacachexia syndrome, inflammatory bowel disease (IBD), and HIV, where HRQoL had been
assessed. Six of the studies contained data regarding pain, and the authors report only a “weakly
positive” improvement in HRQoL (Goldenberg et al. 2017). Of the five studies that evaluated
HRQoL in patients with MS, four of them found no improvement with cannabinoids. The one
study that did report an improvement in HRQoL did so just three months into the study, but they
were unable to show a change from baseline at 12 months into the study. HRQoL in ALS, TBI,
and cancer related anorexia-cachexia all remained unchanged from baseline in the one study that
evaluated the conditions. One study evaluated the change in HRQoL in IBD with smoked
marijuana, and the initial findings reported did show an improvement, but the authors indicate
that the study was very limited and only served to prove that more research is required.
Marijuana use in treating HIV was included in two studies that found mental HRQoL actually
decreased, while another cross-sectional study reported a decreased mental HRQoL but not a
reduced physical HRQoL. The final conclusion made by the authors was that no relationship
exists between marijuana, cannabinoids, and HRQoL.
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The outcome of this study was somewhat predictable. The authors pointed out that the
material used for their analysis consisted of studies that used small sample sizes, were of short
duration, and in which HRQoL was a secondary outcome. In addition, they pointed out that the
HRQoL was evaluated using multiple means of measurement. The authors did try to take every
measure to ensure that the risk of bias was minimized as much as possible, but they still
acknowledged that several of the included studies failed at least four of the bias and quality
criteria. Despite the shortcomings of this systematic review, the authors were very forthcoming
with the limitations concerning the extracted data. Regardless, the findings of the study do not
have enough significance to allow for sound medical decision making. While federal law has
largely prevented, or at least limited, research concerning the use of medical marijuana and
cannabinoids, transitioning to the evaluation of prescription opiates provides researchers with a
myriad of recently collected data of varying reliability.
Manalo et al. (2018) conducted a retrospective review of patients who underwent total
knee arthroplasty (TKA). Two cohorts were entered into the study. One cohort consisted of 137
patients who did not use opioid pain medications preoperatively. The second cohort consisted of
30 patients who did use opioid pain medications prior to TKA. However, missing data from the
patient charts decreased the number of individuals in each cohort, and the final data was
compared between 55 patients in the non-opiate group and 12 patients in the opiate-using group.
Age, sex, and BMI were used to closely compare individuals in each cohort. The authors
compared the EQ-5D scores, which is a standardized measure of health status completed by the
patient, the EQ VAS, which allows the patient to self-rate their overall health on a 20 cm
vertical, visual analog scale, and the UCLA activity scores. After the data was analyzed, the
authors reported that the TKA patients who had used opioid pain medications prior to surgery
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had significantly lower VAS scores, lower UCLA PROM scores, and lower EQ-5D scores when
compared to the non-opioid cohort (p < 0.005). In addition, the non-opioid group was found to
have statistically significant higher EQ VAS scores before (p = 0.043) and after (p = 0.007) the
TKA when compared to the opioid-using group. The data also indicated that preoperative
opiates, and diabetic medication use were the two most significant medication classes that were
present when patients had increased lengths of hospitalization, increased complications, and
increased readmission rates. The final reported conclusion was that an inferior health related
quality of life after TKA is associated with preoperative opioid analgesic medication.
As noted by the authors, this small sample size, especially in the opioid using group, calls
into question the reliability of the data obtained. Another limiting factor was that the data used
was obtained from one hospital instead of multiple hospitals that possibly use different
techniques. This study also only evaluated patients undergoing a TKA, and this prevents
generalization of the data to other forms of surgical procedures. Overall, the data obtained is
consistent with the findings of other studies, which the authors noted. It was indicated that the
data only reinforces the need for further studies concerning opioid medication use. The most
important finding of the study in relation to the literature review is the possible link between
preoperative opiate use and a decrease in health-related quality of life.
In 2017, Thornton, Goyat, Dwibedi, & Kelly conducted a systematic review and metaanalysis to determine if any association existed between long-term opioid use, Physical
Component Scores (PCS), and Mental Component Scores (MCS). Inclusion in the study
required prior studies to be a randomized controlled trial, have an opioid intervention group, a
four-week pain duration at a minimum, a control group, participants over 18 years of age, and
had been conducted prior to April 1, 2016. The final number of included studies in the meta-
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analysis was 19. The researchers divided the study into three groups: Opioid treatment group
versus opioid control group, opioid treatment group versus placebo control group, and a
combination of all of the treatment groups versus the control groups. After statistical analysis,
the authors concluded that treating pain with opioid analgesics of any kind improved the HealthRelated Quality of Life (HRQoL). Specifically, the PCS improvements were noted in the opioid
treatment versus opioid control group (95% CI [0.05 – 0.50]), opioid versus placebo group (95%
CI [0.08 – 0.28], and all treatment groups versus the control group (95% CI [0.11 – 0.32]).
Eight of the studies used evaluated the MCS of patients on long-term opiate therapy, but the
authors reported “moderate to high inconsistencies” in these scores (Thornton et al., 2017). As a
result, the authors reported that improvement of HRQoL was limited to the Physical Component
Scores and only applied to pain and physical function.
There are several factors that limited the quality of the data obtained during this study.
First, all of the studies combined had a mean duration of 15.3 weeks. The second limiting factor
was that the HRQoL was evaluated using several different formats that varied between studies.
Both of these limiting factors were indicated by the authors. The third limiting factor was that
two of the studies included were funded by Purdue Pharmaceuticals, both of which reported no
significant differences between cohorts. Purdue Pharmaceuticals generates significant revenue
from the sale of prescription opiates. A 2009 article published in the American Journal of Public
Health reports that when Purdue Pharma introduced Oxycontin in 1996, aggressive promotion of
the drug increased revenue from $48 million in 1996 to $1.1 billion in Oxycontin sales by the
year 2000 (Zee, A.V., 2009). Overall, the data obtained from the study is inconsistent with what
is known about the long-term effects of opioid analgesic use in chronic pain. That is, while pain
may very well be decreased, long-term treatment with opioid analgesics, especially with higher
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doses, does not equate to improved functioning in society. To suggest otherwise does not
correspond to the effects that society is currently seeing play out in real-time.
Discussion
It is well known throughout the medical community that the current practices of using
prescription opiates for pain management are not sustainable. Healthcare providers are
increasingly unwilling to expose themselves to scrutiny by prescribing opiate analgesics, and
referrals to pain management clinics are becoming more frequent. Unfortunately, there are not
enough pain management clinics to provide care to all of the patients. A suitable alternative to
opioid pain medication must be found. Medical marijuana is currently being legalized across the
country at the state level. This trend almost insures that healthcare providers will be approached
by patients who want to try to control their pain without prescription opiates by adding medical
marijuana. This will require providers to be familiar with the conditions that might benefit from
the use of medical marijuana. Providers will also need to consider the side effects of medical
marijuana when compared to prescription opiates because simply decreasing or eliminating pain
cannot be considered alone. The current literature does not indicate that medical marijuana is
suitable for the treatment of acute pain, which is supported by the data provided by Stevens and
Higgins. In fact, Solattolo et al. found that the use of marijuana is likely to make it more difficult
to treat acute pain, at least in the instances of traumatic injury. In fact, the extreme lack of
current literature regarding the use of marijuana in the setting of acute pain is suggestive that
marijuana is widely considered unacceptable to use on acute pain. In contrast, the current
research is highly variable, but it does suggest that medical marijuana can likely play a role in
managing some chronic pain syndromes in some individuals, which is supported by the data
published by Wilsey et al. and Nurmikko et al. The problem with using current literature to
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make a medical decision to treat chronic pain with medical marijuana is that there has been little
to no evaluation of marijuana strains in specific pathological processes. It is not possible to
generalize the use of marijuana for all chronic pain just like it is not possible to generalize the
use of all non-steroidal anti-inflammatory drugs (NSAIDS) for chronic pain. This is akin to
saying that all opiates have the same ability to control pain. A huge variability exists between
strains of cannabis and cannabinoids, and this variability will require more specific research to
determine exactly what pathological processes can be treated and to determine which patients
might benefit from their use. Unfortunately, most of the current research lumps all marijuana
and other cannabinoids into one group.
When evaluating the addiction profiles of prescription opiates and marijuana, there seems
to be little comparison. Prescription opiates are highly addictive, especially when used longterm, and there is significant risk of respiratory depression and death when misused, while
abdominal pain is a frequent result of consuming too much marijuana. Regardless, the current
opioid crisis in the U.S. seems to speak for itself when considering how this crisis came about,
overprescribing by providers and misuse by patients. The current literature suggests at least a
partial solution to the current opioid crisis may be the use of medical marijuana as supported by
Livingston et al. Unfortunately, there was no to determination whether MVC and other accident
death rates increased due to increased use of marijuana. The actions that are occurring every day
across the U.S. in healthcare settings is perhaps the biggest indicator of how the addiction
profiles of marijuana and prescription opiates differ. Across the country, prescriptions for
opiates are decreasing while prescriptions for medical marijuana are increasing.
The current literature regarding the adverse effects of medical marijuana did not prove to
be particularly useful for decision making. The data published by Gruber et al. did not
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adequately disprove that no marijuana use had no effect on executive function, but the warning
by the National Institute on Drug Abuse regarding the effects of marijuana on memory,
especially with heavy use during teenage years, cannot be discounted. This fact alone should
make healthcare providers question any prescribing of marijuana to teenagers unless the benefits
greatly outweigh the risks. The study conducted by Paulozzi, which was published in 2012,
seems to be a predictor of the current opioid crisis in the U.S. when he determined that the opioid
death rates in 2008 had surpassed the death rate for motor vehicle deaths. This information
raises the question of how the country has found itself dealing with the current opioid crisis and
is a stark reminder that the required research must be completed prior to the complete acceptance
of the use of medical marijuana by the healthcare profession.
Perhaps the most valuable aspect of this issue is the comparison between the quality of
life when using medical marijuana or cannabinoids against the quality of life when taking
prescription opiates. What is the quality of life of a patient who is using mind-altering
medications when they cannot drive to work, school, or the grocery store legally? How good is
the quality of life when a patient spends the majority of every day in bed because the treatment
makes them too sleepy to participate in daily activities? The current literature indicates that
medical marijuana may provide a better health related quality of life than prescription opiates as
supported by Thornton et al. The available data regarding the effects of prescription opiates on
health-related quality of life did not adequately support the published conclusions. Regardless, it
must be acknowledged that both Medical marijuana and prescription opiates are mind-altering
substances. This fact alone will substantially limit quality of life, and it also makes this a
difficult area to measure and can only be based off of how the patient perceives their functional
abilities.
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Application to Clinical Practice
Medical marijuana is not the answer to the opioid crisis in America. The current
evidence does not support the use of medical marijuana for the treatment of acute pain, and there
is only limited preliminary data suggests that medical marijuana can be utilized in the treatment
chronic pain. The literature clearly indicates that medical marijuana can benefit a select
population of chronic pain patients, but more research is required to adequately identify which
patients and conditions respond to treatment. Future research must individually evaluate the
impact of the different strains and the varying potency of marijuana on a variety of chronic pain
syndromes before its use can be safely incorporated into treatments of these syndromes.
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